Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
Neurocrine Biosciences (Nasdaq: NBIX) announced participation in upcoming investor conferences. CEO Kevin Gorman will present at the Cowen 42nd Annual Virtual Health Care Conference on March 8, 2022, at 9:10 a.m. ET. He and CFO Matt Abernethy will also present at the Barclays Global Healthcare Conference on March 16, 2022, at 3:50 p.m. ET in Miami. Additionally, Kyle Gano will speak at the 1st Annual Needham Virtual Neuroscience Forum on the same day at 1:50 p.m. ET. Webcasts will be available on the company's website.
- None.
- None.
SAN DIEGO, March 1, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:
- Kevin Gorman, Chief Executive Officer, will present at the Cowen 42nd Annual Virtual Health Care Conference at 9:10 a.m. Eastern Time on Tuesday, Mar. 8, 2022.
- Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 3:50 p.m. Eastern Time on Wednesday, Mar. 16, 2022 in Miami.
- Kyle Gano, Chief Business Development and Strategy Officer, will present at the 1st Annual Needham Virtual Neuroscience Forum at 1:50 p.m. Eastern Time on Wednesday, Mar. 16, 2022.
The live presentations will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentations will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-301493223.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When will Neurocrine Biosciences present at the Cowen Conference?
Who will present at the Barclays Global Healthcare Conference for Neurocrine Biosciences?
What time will Neurocrine Biosciences present at the Needham Neuroscience Forum?
Where can I watch the live presentations by Neurocrine Biosciences?
What stock symbol is Neurocrine Biosciences listed under?
